{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"100.0"},{"groupId":"OG002","value":"100.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"description":"An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment.","groups":[{"description":"Participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle PLUS nab-paclitaxel IV on Days 1, 8 and 15 of each 28-day cycle.","id":"OG000","title":"Part 1: Pembrolizumab + Nab-Paclitaxel"},{"description":"Participants received pembrolizumab 200 mg IV on Day 1 of each 21-day cycle PLUS paclitaxel IV on Days 1, 8 and 15 of each 28-day cycle.","id":"OG001","title":"Part 1: Pembrolizumab + Paclitaxel"},{"description":"Participants received pembrolizumab 200 mg IV on Day 1 of each 21-day cycle PLUS gemcitabine/carboplatin (gemcitabine) and an Area Under the Curve (AUC) 2 (carboplatin) on Days 1 and 8 of each 21-day cycle.","id":"OG002","title":"Part 1: Pembrolizumab + Gemcitabine/Carboplatin"}],"paramType":"NUMBER","populationDescription":"All randomly assigned participants who received at least 1 dose of study intervention were included in the group corresponding to the study intervention actually received. Four participants assigned to the pembrolizumab + paclitaxel group received incorrect chemotherapy in error: 3 participants received pembrolizumab + nab-paclitaxel and 1 received pembrolizumab + gemcitabine/carboplatin.","reportingStatus":"POSTED","timeFrame":"Up to approximately 39 months","title":"Part 1: Percentage of Participants Who Experienced an Adverse Event (AE) - All Participants","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}